Literature DB >> 22010211

Eph-B2/ephrin-B2 interaction plays a major role in the adhesion and proliferation of Waldenstrom's macroglobulinemia.

Feda Azab1, Abdel Kareem Azab, Patricia Maiso, Teresa Calimeri, Ludmila Flores, Yang Liu, Phong Quang, Aldo M Roccaro, Antonio Sacco, Hai T Ngo, Yong Zhang, Brittany L Morgan, Ruben D Carrasco, Irene M Ghobrial.   

Abstract

PURPOSE: The ephrin receptors (Eph) are found in a wide range of cancers and correlate with metastasis. In this study, we characterized the role of Eph-B2 receptor in the interaction of Waldenstrom's macroglobulinemia (WM) cells with the bone marrow microenvironment. EXPERIMENTAL
DESIGN: We screened the activity of different receptor tyrosine kinases in WM patients and found that Eph-B2 was overexpressed compared with control. Also, we tested the expression of ephrin-B2 ligand on endothelial cells and bone marrow stromal cells (BMSC) isolated from WM patients. We then tested the role of Eph-B2/Ephrin-B2 interaction in the adhesion of WM cells to endothelial cells and BMSCs; the cell signaling induced by the coculture in both the WM cells and the endothelial cells; WM cell proliferation, apoptosis, and cell cycle in vitro and tumor progression in vivo; and in angiogenesis.
RESULTS: Eph-B2 receptor was found to be activated in WM patients compared with control, with a 5-fold increase in CD19(+) WM cells, and activated cell adhesion signaling, including focal adhesion kinase, Src, P130, paxillin, and cofilin, but decreased WM cell chemotaxis. Ephrin-B2 ligand was highly expressed on endothelial cells and BMSCs isolated from WM patients and on human umbilical vein endothelial cells and induced signaling in the endothelial cells promoting adhesion and angiogenesis. Blocking of ephrin-B2 or Eph-B2 inhibited adhesion, cytoskeletal signaling, proliferation, and cell cycle in WM cells, which was induced by coculture with endothelial cells and decreased WM tumor progression in vivo.
CONCLUSION: Ephrin-B2/Eph-B2 axis regulates adhesion, proliferation, cell cycle, and tumor progression in vivo through the interaction of WM with the cells in the bone marrow microenvironment.
© 2011 AACR.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22010211     DOI: 10.1158/1078-0432.CCR-11-0111

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  13 in total

1.  CXCR4 Regulates Extra-Medullary Myeloma through Epithelial-Mesenchymal-Transition-like Transcriptional Activation.

Authors:  Aldo M Roccaro; Yuji Mishima; Antonio Sacco; Michele Moschetta; Yu-Tzu Tai; Jiantao Shi; Yong Zhang; Michaela R Reagan; Daisy Huynh; Yawara Kawano; Ilyas Sahin; Marco Chiarini; Salomon Manier; Michele Cea; Yosra Aljawai; Siobhan Glavey; Elizabeth Morgan; Chin Pan; Franziska Michor; Pina Cardarelli; Michelle Kuhne; Irene M Ghobrial
Journal:  Cell Rep       Date:  2015-07-16       Impact factor: 9.423

2.  Novel Molecular Mechanism of Regulation of CD40 Ligand by the Transcription Factor GLI2.

Authors:  Weiguo Han; David A Jackson; Stephan J Matissek; Jason A Misurelli; Matthew S Neil; Brandon Sklavanitis; Nansalmaa Amarsaikhan; Sherine F Elsawa
Journal:  J Immunol       Date:  2017-05-01       Impact factor: 5.422

Review 3.  The bone marrow microenvironment in Waldenström macroglobulinemia.

Authors:  Amit Agarwal; Irene M Ghobrial
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2013-03-13

Review 4.  Novel treatment options for Waldenström macroglobulinemia.

Authors:  Houry Leblebjian; Amit Agarwal; Irene Ghobrial
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2013-09

5.  3D tissue-engineered bone marrow as a novel model to study pathophysiology and drug resistance in multiple myeloma.

Authors:  Pilar de la Puente; Barbara Muz; Rebecca C Gilson; Feda Azab; Micah Luderer; Justin King; Samuel Achilefu; Ravi Vij; Abdel Kareem Azab
Journal:  Biomaterials       Date:  2015-09-12       Impact factor: 12.479

6.  Identification of ILK as a novel therapeutic target for acute and chronic myeloid leukemia.

Authors:  Pilar de la Puente; Ellen Weisberg; Barbara Muz; Atsushi Nonami; Micah Luderer; Richard M Stone; Junia V Melo; James D Griffin; Abdel Kareem Azab
Journal:  Leuk Res       Date:  2015-09-09       Impact factor: 3.156

7.  CXCR7-dependent angiogenic mononuclear cell trafficking regulates tumor progression in multiple myeloma.

Authors:  Abdel Kareem Azab; Ilyas Sahin; Michele Moschetta; Yuji Mishima; Nicholas Burwick; Johann Zimmermann; Barbara Romagnoli; Kalpana Patel; Eric Chevalier; Aldo M Roccaro; Irene M Ghobria
Journal:  Blood       Date:  2014-09-18       Impact factor: 22.113

8.  Inhibition of CXCR4 in CML cells disrupts their interaction with the bone marrow microenvironment and sensitizes them to nilotinib.

Authors:  E Weisberg; A K Azab; P W Manley; A L Kung; A L Christie; R Bronson; I M Ghobrial; J D Griffin
Journal:  Leukemia       Date:  2011-12-20       Impact factor: 11.528

9.  Ephrin-B2/Fc promotes proliferation and migration, and suppresses apoptosis in human umbilical vein endothelial cells.

Authors:  Li-Chun Zheng; Xiao-Qing Wang; Kun Lu; Xiao-Ling Deng; Cheng-Wei Zhang; Hong Luo; Xu-Dong Xu; Xiao-Man Chen; Lu Yan; Yi-Qing Wang; Song-Lin Shi
Journal:  Oncotarget       Date:  2017-06-20

10.  Eph/Ephrin-mediated stimulation of human bone marrow mesenchymal stromal cells correlates with changes in cell adherence and increased cell death.

Authors:  David Alfaro; Agustín G Zapata
Journal:  Stem Cell Res Ther       Date:  2018-06-26       Impact factor: 6.832

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.